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Tumors are composed of multiple cell types besides
the tumor cells themselves, including innate immune
cells such as macrophages. Tumor-associated mac-
rophages (TAMs) are a heterogeneous population of
myeloid cells present in the tumor microenvironment
(TME). Here, they contribute to immunosuppression,
enabling the establishment and persistence of solid
tumors as well as metastatic dissemination. We
have found that the pattern recognition scavenger
receptor MARCO defines a subtype of suppressive
TAMs and is linked to clinical outcome. An anti-
MARCO monoclonal antibody was developed, which
induces anti-tumor activity in breast and colon carci-
noma, as well as in melanoma models through re-
programmingTAMpopulations to a pro-inflammatory
phenotype and increasing tumor immunogenicity.
This anti-tumor activity is dependent on the inhibitory
Fc-receptor, FcgRIIB, and also enhances the efficacy
of checkpoint therapy. These results demonstrate
that immunotherapies using antibodies designed to
modifymyeloidcellsof theTMErepresent apromising
mode of cancer treatment.
INTRODUCTION
Immunotherapy is now a firmly established anti-tumor treatment
approach, either alone or in combination with more-traditional
treatment options such as chemotherapy (Dougan and Dranoff,2000 Cell Reports 15, 2000–2011, May 31, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://2009). Immune-modulating agents, most importantly mono-
clonal antibodies (mAbs), are widely used both as monothera-
pies and as adjuvants conditioning the tumor microenvironment
(TME) for combinatorial treatments. Recent approval for the clin-
ical use of immune checkpoint Ab therapies that enhance tumor-
specific T cell immunity and restrict tumor immune tolerance
offers potent ways to treat and even cure many types of cancer
(Sharma and Allison, 2015). The TME is a complex structure that
evolves with tumor progression to promote metastatic spread. It
includes regulatory lymphocytes, but also myeloid cells, repre-
sented by different populations of macrophages known as
tumor-associated macrophages (TAMs) and myeloid-derived
suppressor cells (MDSCs) (Solito et al., 2014). TAMs differentiate
from myeloid cells driven by cues from the growing tumor. As a
reflection of the extreme plasticity of macrophages, the pheno-
type and composition of TAMs vary between tumor types, a
number of subpopulations existing with overlapping functions
(Mosser and Edwards, 2008). TAMs support tumor progression
by blocking anti-tumor immunity and by secreting factors that
promote angiogenesis and re-activation of epithelial-to-mesen-
chymal transition (EMT), which enhance metastasis (Fuxe and
Karlsson, 2012). In the TME of many solid tumors, the composi-
tion of TAMs is dominated by myeloid cells with suppressive
capacity (Franklin et al., 2014; Noy andPollard, 2014). The immu-
nosuppressive effect of TAMs stems from their enzymatic ac-
tivities and production of anti-inflammatory cytokines, such as
interleukin-10 (IL-10) and transforming growth factor b (TGF-b),
that have an inhibitory effect on tumoricidal lymphocytes, yet
augment regulatory lymphocyte populations. Selective targeting
of immunosuppressive TAMs in the TME in ways that could
synergize with T-cell-targeted therapies thus presents an attrac-
tive way forward. A variety of macrophage markers have been).
creativecommons.org/licenses/by-nc-nd/4.0/).
investigated for selective expression on immunosuppressive
TAMs and have been evaluated for correlation with clinical
outcome (Bergamaschi et al., 2008). Recently, the ‘‘macrophage
receptor with collagenous structure’’ (MARCO), which is a
pattern-recognition receptor of the class A scavenger receptor
family, was identified as a gene overexpressed in the TME and
linked to poor prognosis of human breast cancer (Bergamaschi
et al., 2008; Elomaa et al., 1995). However, the role of MARCO
in cancer progression and the nature of the cells that express
the receptor in the TME are currently unknown.
Ab-based therapies are often designed to trigger the cytotoxic
activity of effector lymphocytes through the interaction of their
constant region (Fc) with activating FcR on myeloid cells or
NK cells, leading to Ab-dependent cellular cytotoxicity (ADCC)
(Clynes et al., 2000; Taylor and Lindorfer, 2008). However, recent
reports highlight the emerging use of Abs that recruit immune
modulatory effector activities through the engagement of the
inhibitory FcgRIIb (Li and Ravetch, 2011). This highlights the
importance of investigating the Fc dependence of Abs to be
used in the clinic to ensure that they are effective.
Herein, we used three preclinical mouse tumor models, the
4T1 mammary carcinoma, MC38 colon cancer carcinoma, and
the B16 melanoma models, to characterize the expression of
MARCO in the TME and to assess its role in tumor progression.
We found that MARCO expression defines a subtype of TAMs
with an M2-like immunosuppressive gene signature in the
TME of both mammary carcinoma and melanoma. Using anti-
MARCO mAbs to target these TAMs, we induced anti-tumor
activity in both the primary and metastatic breast carcinoma as
well as in the primarymelanoma tumormodels. The anti-MARCO
treatment led to alteration of the composition of TAMs in the TME
into a pro-inflammatory population, thereby rendering the tumor
immunogenic. We also found that anti-MARCO increases the ef-
ficacy of checkpoint therapy using anti-CTLA4 in bothmelanoma
and colon cancer models. The anti-tumor activity was depen-
dent on the ability of the Fc of the anti-MARCO mAbs to engage
the inhibitory Fc-receptor, FcgRIIB. Based on this finding and on
the fact that MARCO expression is associated with a more-reac-
tive TME signature in human breast cancer and human mela-
noma, these results demonstrate that immunotherapies using
Abs designed to modulate myeloid cells of the TME represent
a promising new mode of cancer treatment.
RESULTS
Identification of MARCO Expression on
Immunosuppressive TAMs in the TME of Murine
Mammary Carcinoma, Melanoma, and Colon Carcinoma
MARCO has a restricted expression profile on tissue-resident
macrophages in the lung, lymph nodes, spleen, and peritoneum
as well as on activated dendritic cells (DCs) (Matsushita et al.,
2010). To investigate whether it was expressed in tumor stroma
of mice, we investigated mammary carcinoma (4T1) injected in
mammary fat pads as well as in melanoma (B16) and colon
carcinoma (MC38) growing subcutaneously (s.c.). Using immu-
nofluorescent staining, we found that, in the 4T1 mammary car-
cinoma, MARCO was co-expressed on CD11b+F4/80+ TAMs
(Figure 1A). Likewise, in the B16 melanoma model, MARCO+TAMs also stained positively for both CD11b and F4/80, and in
addition, MARCO+ TAMswere also found in theMC38 colon car-
cinoma model (Figures 1B and 1C).
Importantly, MARCO was not expressed on other myeloid
cells or lymphocytes including CD11c+ DCs, PDCA+ DCs,
M1-like macrophages, TCRb+ T cells, B220+ B cells, and
NK1.1+ natural killer (NK) cells (Figures S1A and S1B). We also
verified that DCs in the tumors did not express MARCO using
qPCR on sorted cells. Thus, in summary in the B16 melanoma,
MARCO is only expressed by F4/80+CD11c TAMs. Inter-
estingly, we also found that, in the melanoma model, the
MARCO-expressing TAMs were not equally distributed but
were situated close to the capsule in the TME (Figure S1C). To
further dissect which subtype of TAMs expressed MARCO, we
sorted CD45+CD11b+ TAMs from B16 tumors into four subpop-
ulations based on their expression of Ly6C andMHCII (Movahedi
et al., 2010; Figure 1D). These TAM populations represent
Ly6ChighMHCIIlow inflammatory monocytes, Ly6ChighMHCIIhigh
immature macrophages, Ly6Cint.MHCIIhigh classically activated
(M1), and Ly6ClowMHCIIlow alternatively activated (M2) mac-
rophages, respectively. Using this categorization, M2 macro-
phages have been described to be immunosuppressive and
tumor promoting in vivo, whereas M1 macrophages are inflam-
matory and can eradicate tumors (Noy and Pollard, 2014).
Because macrophages in general are very plastic, we used
qPCR to further define the TAM populations with respect to
MARCO expression (Figure 1E). We found that MARCO was
most highly expressed in the Ly6ClowMHCIIlow M2-like (M2) sub-
population, which also expressed the M2 markers cx3cr1, arg1,
and retnla (fizz1) but showed low expression of the M1-associ-
ated markers h2-ab1 (mhcII) and nos2 (inos) (Figure 1F). Thus,
MARCO is expressed by TAMs with an M2 gene signature in
the TME.
MARCO Expression Is Promoted by the Tumor and
M2-Polarizing Cytokines
TheexpressionofMARCOon immunosuppressiveM2TAMswas
further supported by in vitro polarization of bone-marrow-derived
macrophages (BMDMs) using tumor supernatant or cytokines.
MARCO was upregulated on M2-polarized macrophages as
well as on TAMs differentiated with supernatant from B16
melanoma cells (Figure 2A). These in-vitro-derived MARCO+
CD68+MHCIIlowLy6C+-expressing macrophages induced by
tumor supernatant also co-expressed M2 markers such as
CD115 and CD206 by flow cytometry as well as M2-connected
genes, including cytokines Csf1r, Il10, Arg1, Retnla, and Chi3l3,
as well as genes connected to an M2-like phenotype, Tgfb,
cx3cr1, and ccr2, but not M1 genes (H2-ab1, Nos2, and
Il12a/b), as determined by qPCR (Figures 2B and 2C). Consid-
ering the fact that cytokines, such as IL-10 and TGF-b, are
frequently overexpressed in the TME and can promoteM2 polar-
ization of macrophages, we studied whether these cytokines
could affect MARCO expression. Indeed, we found that the
expression of MARCO induced by the B16 tumor supernatant
stimulation of a peritoneal macrophage cell line could be
mimickedbyusing IL-10or TGF-b stimulationofM0BMDMs (Fig-
ures S2A and S2B). Blocking experiments using Abs against IL-
10 and/or TGF-b for tumor supernatant upregulation of MARCOCell Reports 15, 2000–2011, May 31, 2016 2001
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Figure 1. Identification of MARCO as a
Marker on M2 Macrophages in Tumor
Stroma of Mammary Carcinoma, Melanoma,
and Colon Carcinoma
(A) Immunofluorescence (IF) staining of 4T1 mam-
mary tumor sections. MARCO (red) as an individual
channel (left) and merged (right) with CD11b
(green) and F4/80 (blue) is shown.
(B) IF staining of B16 melanoma tumor sections.
MARCO (red) in an individual channel (left) and
merged (right) withCD11b (green), F4/80 (magenta),
and DAPI (blue) is shown.
(C) IF staining of MC38 colon tumor sections.
MARCO (red) in an individual channel (left) and
merged (right) with F4/80 (blue) is shown. All
magnifications are 633.
(D) Flow cytometric analysis of macrophage sub-
populations sorted from B16 tumors on D10. The
cells were gated on live CD45+CD11b+ single cells
and subsequently divided into four TAM subtypes
based on Ly6C and MHCII expression; (right)
Ly6Chi MHCIIlo inflammatory monocytes (gray);
Ly6Cint MHCIIhi immature macrophages (green);
Ly6Clo MHCIIhi M1 TAMs (blue); and Ly6Clo
MHCIIlo M2 TAMs (black). (Left) Graphical illus-
tration of color-coded sorted macrophage pop-
ulations, from B16 tumors, is shown.
(E) Relative expression of MARCO on sorted
macrophages subpopulations from (D) normalized
to inflammatory monocytes (gray).
(F) Relative expression of M1 and M2 genes by
qPCR on macrophage subpopulations from (D).
In (D), data show mean ± SEM with a confidence
interval (CI) of 95% of duplicates from one out of
three representative experiments.were unsuccessful (data not included), possibly due to additional
factors or affected by the fact that the supernatant induced pro-
duction of these cytokines by macrophages themselves (Fig-
ure 2C). These data implicate MARCO expression on TAMs in
the re-activation of EMT, which is driven by TGF-b and acts as
a link between inflammation and cancer progression toward
metastasis (Fuxe andKarlsson, 2012;Mani et al., 2008;Miettinen
et al., 1994). Collectively, these data show that MARCO expres-
sion is driven by cytokines that are released in the TME and
that it is a general marker for immunosuppressive macrophages.
Immunotherapy Targeting MARCO Arrests Tumor
Growth and Metastasis and Increases TME
Immunogenicity
Based on the restricted expression pattern of MARCO on tumor-
promoting TAMs, we next assessed whether MARCO could
be used as a target for immunotherapy. Wild-type mice were
thus injected with 4T1 cells in the mammary fat pad, and a
MARCO-specific Ab was given intravenously (i.v.) followed by
monitoring of tumor growth and measuring of metastasis (Fig-
ure 3A). We found that anti-MARCO immunoglobulin G (IgG)
had the ability to reach MARCO-expressing TAMs in the 4T1
mammary fat pad carcinoma TME (Figure 3B). In addition, 4T1
tumor-bearing mice that were treated with anti-MARCO IgG
had smaller tumors measured, as both tumor volume and
weight, compared to untreated mice (Figure 3C). We also2002 Cell Reports 15, 2000–2011, May 31, 2016observed that treatment with anti-MARCO IgG significantly
reduced metastatic spread to the lungs as determined by
in vitro cultures of tumor cells from the lungs of the mice (Fig-
ure 3D). Furthermore, we found that treatment with anti-MARCO
IgG resulted in a shift in the composition of TAM populations in
the TME of 4T1 tumors, with an increase in M1 TAMs and a
concomitant decrease of the M2 TAM population (Figure 3E).
To determine whether this shift rendered the tumor more immu-
nogenic, we characterized the draining lymph nodes and
observed increased germinal center formation as well as altered
CD4/CD8 T cell ratio and a tendency for reduced numbers of
T regulatory cells (Figures 3F and 3G).
The 4T1 mammary tumor is a potent inducer of MDSCs, which
are a heterogeneous group of immature myeloid cells that sup-
press T cell activation and accumulate in the spleen during
cancer (Sinha et al., 2007; Solito et al., 2014). We next explored
the possibility that anti-MARCO treatment affected this pop-
ulation of cells. However, we could find no evidence for
changes in either the monocytic (M-MDSC) or polymorphonu-
clear (PMN-MDSC) subpopulations in the spleens of tumor-
bearing mice (Figure S3A). In addition, we did not observe any
alterations in other lymphocyte populations including macro-
phages, B cells, T cells, NKT cells, or NK cells (Figures S3B–
S3D). Anti-MARCO treatment therefore specifically alters TAM
populations to increase immunogenicity of the tumor, and this
in turn stops growth and metastatic spread to the lungs.
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Figure 2. Association of MARCO with M2- and Tumor-Polarizing Expression Signatures
(A) IF stainings (633) on M0, M2, and TAM (B16 tumor-supernatant)-polarized BMDMs. MARCO (red) in an individual channel (left) and merged (right) with F4/80
(blue) and CD11b (green) is shown.
(B) Flow cytometric analysis of surface marker expression on M0, M1, M2, and TAM-polarized BMDMs.
(C) Relative expression of M1 andM2 genes by qPCR onM0, M1, M2, and TAM-polarized BMDMs. In (C), data showmean ± SEMwith a CI of 95% of duplicates.Anti-MARCO Therapy Restricts Tumor Growth in a
Melanoma Model and Promotes Immune Checkpoint
Therapy
To evaluate the generality of anti-MARCO immunotherapy and to
further dissect its mechanism of action, we tested its efficacy in
the B16 melanoma model (Figure 4A). To create a targetable
stromal compartment, B16 melanoma cells expressing lucif-
erase were injected subcutaneously in Matrigel in the flanks
of mice. These mice were subsequently treated with anti-
MARCOmAbs, and tumor growth wasmeasured using an in vivo
imaging system (Figure S4A). As in the 4T1 mammary tumor
model, when injected i.v. into tumor-bearing mice, the anti-
MARCO Abs reached MARCO+ TAMs in the stroma (Figure 4B).
Likewise, the treatment significantly reduced tumor growth over
the 9 days of experimental observation (Figure 4C). The TME dis-
played similar changes as were observed in the 4T1 model
with decreased numbers of immature macrophages, an altered
CD4/CD8 ratio, decreased numbers of regulatory T cells, and
an increased CD4/T-reg cell ratio, whereas no effect was evident
for other lymphocytes or myeloid cells (Figures S4B–S4E). When
investigating gene expression of the bulk of sorted TAMs, wefound general upregulation of M1-related genes including Il1b
as well as a downregulation of Il10, showing a shift of macro-
phage polarization toward M1 (Figure 4D). To directly test
whether anti-MARCO treatment rendered the tumor more immu-
nogenic, we used B16 tumors expressing membrane-bound
ovalbumin (OVA). Here, we found that anti-MARCO increased
the OVA-specific CD8 responses as well as increased the pro-
duction of OVA-specific IgG2b (Figure S4F). Next, the efficacy
of anti-MARCO treatment was compared with immunotherapies
with known activity in this model and we addressed whether it
could enhance ADCC or checkpoint therapy. Groups of mice
were injected with anti-MARCO alone or together with an Ab
against the TRP1 antigen, which induces direct ADCC of the tu-
mor (TA99; Clynes et al., 1998; Thomson et al., 1985; Figure 4E).
We found that anti-MARCO treatment had a similar effect as
TA99 in arresting tumor growth, but there was no apparent addi-
tive effect when combining the two. As an important control,
there was no effect of the anti-MARCO treatment on tumor
growth in MARCO-deficient mice (Figure 4E). In contrast,
combining anti-MARCO treatment with immune checkpoint
therapy using anti-CTLA4 Abs (Leach et al., 1996) decreasedCell Reports 15, 2000–2011, May 31, 2016 2003
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Figure 3. Anti-MARCO Ab Treatment Inhibits Tumor Growth and Metastasis by Increasing the Immunogenicity of the Tumor Microenvi-
ronment in the 4T1 Mammary Carcinoma
(A) Schematic of the 4T1 mammary carcinoma model and Ab treatment regimen.
(B) IF stainings of 4T1 mammary tumors; in vivo administered anti-MARCO Ab is detected in green on F4/80+ (blue) macrophages in 203 (upper panel) and 633
(lower panel).
(C) 4T1 primary tumor volume (left) and weight (right) on D21.
(D) Metastatic index based on volume (left) and weight (right) as measured by lung tumor colony formation assay on D21.
(E) Percentage of 4T1 tumor-infiltrating macrophage subpopulations (same gating strategy as in Figure 1C) on D21.
(F) Percentage of germinal center B cells in 4T1 tumor-draining versus non-draining inguinal lymph nodes in untreated controls and anti-MARCO Ab-treated mice
on D21 and naive inguinal lymph nodes from non-tumor-bearing mice.
(G) 4T1 tumor-infiltrating CD4+/CD8+ T cell ratio on D21 (left). Frequency of tumor-infiltrating T regulatory cells on D21 (right) is shown. Untreated control (open
circle), anti-MARCO Ab (filled black circle), and naive non-tumor-bearing mouse (filled gray circle) are shown.
Data show mean ± SEM with a CI of 95% in one representative out of three independent experiments where n = 5–10/group.tumor growth and also increased survival compared to CTLA-4
treatment alone (Figures 4F and 4G). This was verified in the
MC38 colon carcinoma model, in which anti-MARCO Abs signif-
icantly increased the efficacy of anti-CTLA4 treatment (Fig-
ure 4H). Taken together, these data indicate that anti-MARCO
treatment inhibits the growth of melanoma with a similar im-
mune-modulatory effect as evident in mammary carcinoma.
In addition, anti-MARCO enhances checkpoint therapy using
anti-CTLA4 Abs in bothmelanoma and colon carcinomamodels.
Selective Engagement of FcgRIIb Is Required for the
Anti-MARCO Anti-tumor Effect
Previous studies have showed that anti-tumor Abs require the
engagement of distinct FcRs to either promote cytotoxicity
(Clynes et al., 1998) or to induce agonistic activity through cross-
linking (Li and Ravetch, 2011). To further dissect the mechanism
through which engagement of anti-MARCO on TAMs resulted in
alteration of the TME, we generated recombinant mouse anti-
MARCO Abs with defined Fc domains that selectively engaged
murine FcRs. Using these Fc variants, we determined that the
Ab that was unable to bind FcRs had a diminished therapeutic
effect, suggesting involvement of Fc receptors (Figure 5A). Using
Fc-receptor-deficient mice lacking all Fc receptors or only acti-
vating FcgRI, III, and FcgRIV receptors, respectively (Smith
et al., 2012; Takai et al., 1994), we found that the anti-MARCO2004 Cell Reports 15, 2000–2011, May 31, 2016therapeutic effect was not dependent on activating receptors,
leaving only the inhibitory FcgRIIB to be responsible for the
anti-tumor effect (Figure 5B). To verify the involvement of
FcgRIIB, we also tested the ability of anti-MARCO to decrease
tumor growth in FcgRIIB-deficient mice, which was less effec-
tive (Figure 5B). Supporting a macrophage-intrinsic mechanism,
FcgRIIB was primarily expressed on M2 TAMs as well as
on in vitro bone-marrow-derived TAMs (Figure 5C). FcgRIIB
engagement is required for the agonistic activity of Abs targeting
the tumor necrosis factor receptor (TNFR) superfamily members
CD40 and DR5 (Li and Ravetch, 2011) by facilitating crosslinking
of these trimeric receptors. It is thus likely that the anti-tumor ac-
tivity of the anti-MARCO Ab also results from crosslinking of this
trimeric receptor to modify TAM activation or composition.
Expression of MARCO Correlates to M2 TAM and EMT-
Metastasis-Driving Gene Signatures in Human Basal
Breast Cancer and Metastatic Melanoma
To investigate the clinical relevance of an anti-MARCO treat-
ment, we next investigated the presence of MARCO-positive
TAMs by gene expression and immunohistochemistry on human
primary breast cancer biopsies. Using two different human
breast cancer datasets, we found that MARCO was most highly
expressed in the basal (triple negative) subgroup of patients
compared to LumA, LumB, and Her2+ subgroups (Sørlie et al.,
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Figure 4. Anti-MARCO Ab Treatment Inhibits Tumor Growth and Supports Immune Checkpoint Ab Therapy with Anti-CTLA-4 Ab
(A) Schematic of the B16 melanoma tumor model and Ab treatment regimen.
(B) IF stainings of B16 tumors. In-vivo-administered anti-MARCO Ab (green) detected on F4/80+ (blue) macrophages is shown, 633 (left) and 1003 (right).
(C) B16 tumor growth curves measured by IVIS on untreated and anti-MARCO Ab-treated mice.
(D) M1 and M2 gene expression profile by qPCR of sorted live CD45+CD11b+Ly6G bulk macrophages from untreated and anti-MARCO-treated B16 tumors,
day 12.
(E) Histograms representing B16 tumor size of different combinatorial treatment groups on day 9 in wild-type (WT) and MARCO-deficient mice; n = 10–20/group.
(F) Histograms of B16 untreated, anti-CTLA-4 Ab+Gvax, and anti-CTLA-4 Ab+Gvax+anti-MARCO Ab-treatedmice, n = 5–10/group, of two independent repeats.
(G) Survival analysis of mice challenged with B16 tumor cells and vaccinated on days 3, 6, and 9 with 13 106 Gvax and the indicated Ab or combination i.v. Anti-
MARCO treatment was continued at 3-day intervals. Lack of survival was defined as tumor volume >1,000 mm3, n = 5–10/group. Survival curves were analyzed
according toMantel-Cox log rank test; anti-CTLA-4 Ab+Gvax versus anti-CTLA-4 Ab+Gvax+ anti-MARCOAb; p = 0.0337. In (C)–(E), data showmean ±SEMwith
a CI of 95%. Data show one out of two independent repeats.
(H) Histograms of MC38 untreated, anti-CTLA-4 Ab, and anti-CTLA-4 Ab+anti-MARCO Ab-treated mice; n = 10/group; data are representative of two inde-
pendent repeats.2001; Figures 6A and S5A). The figures show the distribution of
MARCO expression stratified by breast cancer molecular sub-
types. This correlates with our findings of MARCO-expressing
TAMs in mice, as the 4T1 tumor model is considered to some
extent to represent basal breast cancer (Kaur et al., 2012). Pa-
tients with the basal tumor subtype are also those individuals
with the poorest prognosis, and the current treatment options
are limited to cytotoxic agents (Badve et al., 2011). To further
evaluate MARCO expression in human breast tumors, we
compared it to the expression of defined immunosuppressive
TAM markers (ARG1, RETNLB, IL4R, CHIA, CD68, and
CD163), including FcgRIIB. MARCO expression was positively
correlated with all these genes except arg1 in the The Cancer
Genome Atlas (TCGA) dataset, indicating that the receptor is ex-
pressed in cancers with high M2 TAM expression signatures
(Figures 6B and S5B). Next, we correlated MARCO expressionwith expression of a number of EMT markers (Table S1) and
observed that many of these were positively correlated with
MARCO in the tumors (Figures 6C and S5C; Creighton et al.,
2009). Among these genes,mmp9 is involved in tissue remodel-
ing and metastasis (Morini et al., 2000), and snail as well as twist
are considered master regulators of EMT (Xu et al., 2009). We
then used immunofluorescence staining of human breast cancer
tumors to investigate MARCO expression and found it to be co-
expressed on CD68+ M2 TAMs as defined by CD206 and CD163
expression (Figure 6D). When quantifying MARCO+ TAMs in
breast cancer comparing estrogen receptor (ER)+/progesterone
receptor (PR)+ tumors with triple-negative (basal-like) tumors,
we found that there were more TAMs in the triple-negative tu-
mors and that the MARCO+CD163+ M2 subpopulation was
dominant (Figures 6E, 6F, and S5D). When investigating human
metastatic melanoma, we found that MARCO was expressedCell Reports 15, 2000–2011, May 31, 2016 2005
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Figure 5. The Anti-MARCOAnti-tumor Effect IsMediated through an
FcR-Dependent Mechanism
(A) Histograms representing B16 tumor size of mice treated with Fc-modified
anti-MARCO Abs compared to untreated and anti-MARCO Ab-treated mice
on D10; n = 5.
(B) Histograms depicting B16 tumor size in FcRKOmouse strains compared to
wild-type; n = 4–9/group (left) and in FcgRIIb KOmice on D9; two independent
experiments with n = 4/group (right).
(C) Relative expression of FcgRIIb in tumor-infiltrating myeloid populations
(Figure 1C, gates 1–4) compared to inflammatorymonocytes (left) and BMDMs
compared to M0 macrophages (right). Data show mean ± SEM with a CI of
95% of duplicates.
In (A) and (B), data show mean ± SEM with a CI of 95%.more in local and distant metastases (Figure S6A). As with breast
cancer, MARCO expression correlated with macrophage and
M2 TAM-related genes as well as markers of EMT (Figures
S6B and S6C). We also verified MARCO expression by immuno-
fluorescence by triple staining with CD68 and the M2 marker
CD163 (Figure S6D). These data suggest that anti-MARCO
immunotherapy could especially benefit patients suffering from
triple-negative breast cancer carcinoma and could also be effec-
tive in melanoma. Similar to the mouse models, we also found2006 Cell Reports 15, 2000–2011, May 31, 2016that a subpopulation of M2 TAMs expressedMARCO and further
evaluation of this subtype in other cancers is warranted.
DISCUSSION
The success of immune checkpoint therapy has spawned an
intense search for other immune-modulatory treatments for can-
cer, especially those that can further improve these treatments.
Here, we show that using Abs that are specific for the pattern
recognition receptor MARCO expressed by TAMs is a feasible
way to treat mammary carcinoma, colon carcinoma, and mela-
noma, as well as supporting CTLA-4 treatment in two of these
models. In this treatment strategy, we selectively target a spe-
cific subtype of TAMs in the tumor stroma to activate them and
render the tumor immunogenic. This approach was sufficient
to shift the balance of the anti-inflammatory, pro-tumorigenic,
and metastatic TME to a less-supportive one for tumor progres-
sion. As a result, not only tumor growth but also metastatic
spread to the lungs was inhibited. Whereas targeting TAMs
has been highlighted as an attractive alternative to classic tumor
treatment, the only option to date that has shown promise is
cytokine blockade, a pan-macrophage approach that has limited
applicability (DeNardo et al., 2011; Pyonteck et al., 2013; Stra-
chan et al., 2013). The CSF-1 blockade has been evaluated for
tumor treatment and has been tested for the ability to enhance
the response to chemotherapy. The anti-MARCO treatment
also enhanced an anti-tumor effect mediated by anti-CTLA4
Ab therapy in melanoma and colon carcinoma, and further
studies will elucidate how it works in combination with other
treatments. In melanoma, combination of checkpoint therapies
have been effective, but still there are patients that are non-re-
sponders, and optimal use of T-cell-directed treatments will
require combination with other therapies (Larkin et al., 2015;
Twyman-Saint Victor et al., 2015). Combining these with anti-
MARCO treatment would be an attractive way forward to
enhance the efficacy even further without having to resort to a
less-specific treatment. Mechanistically, making tumors more
immunogenic by including an Ab against TAMs would increase
the specific T cell response that could be further enhanced by
anti-CTLA4 treatment. In addition, activating T cells to target
the tumor might further polarize TAMs to a pro-inflammatory
phenotype and support checkpoint therapy. The effect of anti-
CTLA4 depends on the activating FcgRIV expression by macro-
phages (Simpson et al., 2013), whereas here we find that potent
anti-MARCO treatment depends on FcgRIIB expression. This is
similar to what has been reported for anti-CD40 treatment, which
requires this receptor for immunostimulatory activity (Li and Rav-
etch, 2011). This Fc dependence will be an important aspect to
take into consideration when designing anti-MARCO mAb ther-
apeutics for the treatment of cancer.
We determined that MARCO expression correlated with
expression of M2 markers that have been described to be ex-
pressed by tumor-promoting macrophages (Sica et al., 2008).
However, macrophages are extremely plastic cells and tran-
scriptome analyses often show mixed M1 and M2 phenotypes
with several subtypes within each category (Murray et al.,
2014; Qian and Pollard, 2010). We found that MARCO was ex-
pressed by a subpopulation of TAMs in the TME of both murine
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Figure 6. MARCO Targets the Tumor Stroma of Human Triple-Negative Breast Cancer
(A) Expression of MARCO (left panel) in human breast cancer subtypes and subtype distribution in each group (right panel) in the TCGA dataset.
(B and C) Correlation of MARCO expression with the M2 gene set in the TCGA dataset (B) and with the EMT gene set in the TCGA dataset (C).
(D) IF stainings of one representative human triple-negative breast cancer sample (203). (Left panel) MARCO (red), tumor-marker E-cadherin (green), and DAPI
(blue), in individual channels and merged, are shown. (Middle panel) MARCO (red), CD206 (green), tumor-marker E-cadherin (white), and DAPI (blue) and (right
panel) MARCO (red), CD68 (green), CD163 (white), and DAPI (blue) are shown. (Far left panel) Magnification of macrophage-rich area from left panel is shown.
(E) Quantification of CD68+ fluorescence area in ER+/PR+ and triple-negative human breast cancer sections; n = 9/group; each dot represents one sample; three
non-overlapping images were obtained per sample covering the majority of the section, with the exception of one sample due to size limitations.
(F) Pie chart indicating the distribution of different macrophage populations in triple-negative breast cancer samples; n = 5; three images per sample were
counted, except for one sample (only one image) due to size limitation.tumor models and in human cancer. Further characterization of
the MARCO+ subpopulation of TAMs is needed in other cancers
to define to which extent it is clinically relevant for cancer pro-
gression. Previously, it has been shown in vitro that human
monocytes can be activated to express MARCO by glucocorti-
coids (Gratchev et al., 2005), and here, we find that TGF-b and
IL-10 could also upregulate MARCO. This supports MARCO as
a marker for potentially several subtypes of immunosuppressive
TAMs. However, currently, the data available for macrophage
activation are complex, and a clear translation between studies
in vitro and in vivo is difficult as it is challenging tomimic all tissue
or TME-related cues. In addition, activated DCs have been
shown to express MARCO, and this receptor modulates their
migration and efficacy in cellular immunotherapy. Thus, modu-
lation of MARCO may also be useful beyond repolarization
of TAMs.To summarize, this study shows that reprogramming of mac-
rophages in the TME using Abs is a feasible approach for cancer
immunotherapy. These findings lead way for further screening
for possible new targets on TAMs for directed Ab therapy in
models where altered macrophage polarization will be benefi-
cial. To expose the inherited immunogenicity of tumors using
specific Abs has great potential and will also shed light on
the function of the immune system in the context of cancer
surveillance.EXPERIMENTAL PROCEDURES
Cell Culture
The B16 luciferase-transfected (B16-luc) mouse melanoma cell line (kind gift
from Dr. K. Weilbaecher, Washington University) and B16mOVA from
Dr. Thomas Tedder (Duke University School of Medicine) was cultured inCell Reports 15, 2000–2011, May 31, 2016 2007
complete medium (DMEM supplemented with 2 mM L-glutamine, 10 mM
HEPES, and 10% heat-inactivated fetal calf serum [FCS]), and selective
expression of the plasmid bearing the luciferase gene was maintained by
addition of 100 mg/ml Geneticin (G418) once a week during propagation. All
cells used for the individual repeats of the experiment originate from the
same early passage stock and are cultured for 1 week before in vivo admin-
istration. The 4T1 mammary carcinoma cell line (Barbara Ann Karmanos Can-
cer Institute) was cultured in RPMI-1640 medium supplemented with 10%
fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% glutamine.
The MC38 colon adenocarcinoma cell line was culture in RPMI-1640 medium
supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% glutamine.
IC-21 peritoneal macrophage cell line (ATCC) was cultured in RPMI-1640 me-
dium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1%
glutamine. The rat anti-MARCO IgG1 mAb hybridoma ED31 was a generous
gift from Prof. G. Kraal. For generation of in vitro BMDMs, bone marrow
was collected by flushing the femurs of 8- to 10-week-old C57BL/6 or
MARCO KOmice with cold DMEM. After collection, red blood cells were lysed
and the cells were washed twice in PBS. To induce macrophage differentia-
tion, cells were resuspended in DMEM supplemented with 20% FCS and
20% macrophage colony-stimulating factor (M-CSF) conditioned medium
collected from 3- to 4-day cultures of mouse L929 fibroblasts secreting
M-CSF. The cells were plated in different-sized vessels depending on the
application. On day 3, half of the volume was replaced with fresh DMEM/
M-CSF, and on day 6, the entire volume was replenished. On day 10 of
in vitro culture, the cells were polarized using standard conditions as reported
by Mosser and Zhang (2008). More specifically, M1 classical activation was
induced by addition of 20 ng/ml interferon g (IFNg) and 10 ng/ml lipopolysac-
charide (LPS) and M2 alternative activation was induced by addition of
20 ng/ml IL-4 and 20 ng/ml IL-13; for TAMs, a supernatant from in vitro cul-
tures of B16 was applied, and for M0, only DMEM 10% FBS was added.
Alternatively, IC-21 cells and M0 BMDMs were treated with 20 ng/ml IL-10
or TGF-b to induce MARCO upregulation. The cytokines were purchased
from R&D Systems. After polarization, the cells were phenotyped, stimulated
with mAbs, and used in different assays.
Animal Studies
Mice were maintained at the Microbiology Tumor and Cell Biology Animal
Facility at Karolinska Institute, and the experiments were approved by
the local ethical committee (the North Stockholm district court). Wild-type
C57BL/6, Balb/c (Taconic) and MARCO KO and FcRIIb KO (Taconic) on
C57BL/6 mixed background mice were kept and bred under pathogen-
free conditions according to local ethical guidelines. FcRa-null (Smith
et al., 2012), Fcer1g/ (Takai et al., 1994), humanized FcgR mice (Smith
et al., 2012) from J.V.R.’s laboratory at Rockefeller University were used
in B16 tumor experiments and C57BL/6 for the MC38 model. Mice at
the age of 8–10 weeks were injected s.c. in the right flank with 1 3 105
(or 2 3 104 for survival studies) B16-luc or B16mOVA cells in BD Matrigel
(later taken over by Corning). At days 3, 6, and 9 of the experimental setup,
mice were injected i.v. with 50 or 100 mg of anti-MARCO mAb (rat IgG1;
clone ED31), 200 mg TA99 mAb (mouse IgG2a), and or 100 mg anti-
CTLA-4 mAb (9D9) from Bio X cell. The anti-CTLA-4 mAb was used in
combination with 1 3 106 irradiated (150 Gy) B16-BL6 cells expressing
granulocyte M-CSF (GM-CSF; GVAX) that were injected s.c. in the contra-
lateral flank. The animals were imaged using intravital imaging (IVIS) at
the same time points. For the B16 model survival studies, the tumors
were measured manually every second day for the entire duration of the ex-
periments. On day 10 of the experimental setup, the animals were sacrificed
and tumors, spleens, and lymph nodes were collected for further analyses.
Balb/c mice were injected in the mammary fat pad with 2 3 105 syngeneic
4T1 mammary adenocarcinoma cells and treated with 100 mg of anti-
MARCO mAb on days 0 and 3 and thereafter with 50 mg every third day.
Mice were sacrificed on day 21, and primary tumors, lung metastases,
spleens, and draining and non-draining lymph nodes were assessed. In
the MC38 model, 2 3 106 cells were injected s.c. in C57BL/6 mice. Mice
were treated intraperitoneally (i.p.) with 50 mg anti-CTLA-4 Ab on days 7,
10, and 13. Treatment with 200 mg anti-MARCO Ab i.p. was done on days
7, 10, 13, and 17. Tumor size was monitored by manual measurements.2008 Cell Reports 15, 2000–2011, May 31, 2016Cloning and Production of Fc-Modified Variants of the Rat anti-
MARCO IgG1 ED31 mAb
Cloning of the rat (anti-MARCO) IgG CDRs from ED31 hybridoma cDNA was
performed using the 50 RACE system for rapid amplification of cDNA ends.
A list of the primers used is presented in Table S1. Antibody expression vectors
were transfected into competent E. coli cells and cultured to single clones that
were screened for the production of the correct DNA construct. The chosen
clones were expanded for plasmid purification. Plasmids were transfected
into HEK293T cells for production of the different mAbs. Culture supernatants
were collected, and the Abs were isolated by standard protein purification
techniques using G-protein-specific separation columns.
Lung Tumor Colony Formation Assay
Lungs were harvested in PBS + 10% FBS and dissociated in StemPro Accu-
tase medium supplemented with TrypLE at a 1:1 ratio and 1 mg/ml Dnase in
6-well plates. They were subsequently dissected into small pieces and incu-
bated at 37C for 20 min. The tissue was further disturbed by passaging
through a syringe (without the needle) and lastly through a syringe with a nee-
dle for further dissociation. The cell suspension was filtered through a 70-mm
cell strainer followed by treatment with erythrocyte lysis buffer. The lung cells
were resuspended in RPMI-1640 medium containing 60 mM/l 6-thioguanine
(Sigma) and seeded in 10-cm plates. The culture medium was changed after
4 or 5 days. On day 10, the cells were washed and fixed in formaldehyde. After
washing with distilled H2O, the cells were stained with hematoxylin for 5 min
and the plates were dried upside down, after which the number of microcolo-
nies was counted.
Immunofluorescence
Murine tumorswere cryopreserved inOCTmediumNEG50 (ThermoScientific),
and 8-mm-thick sections were cut using a cryostat microtome. After overnight
drying, the slides were fixed in acetone and stored at 80C. Before staining,
slides were blocked with 5% goat serum (DakoCytomation) in PBS. The
following Abs were used: rat anti-MARCO produced by the ED31 hybridoma
andconjugated toAF555 (LifeTechnologies); goat anti-rat IgGAF555 (Life Tech-
nologies); anti-F4/80 AF647/AF488; anti-CD11b AF488; anti-CD11c FITC; anti-
DEC205 AF647; anti-PDCA-1 AF488; anti-TCRb AF488; anti-CD45R AF488;
anti-NK.1.1 Biotin (Biolegend); anti-CD200RAF488 (AbD serotec); and Strepta-
vidin AF488 (Life Technologies). Slides were mounted with Prolong Diamond
mounting medium. Human breast carcinoma cryosections were treated as
above. After blocking with goat serum, primary Abs were incubated overnight
at +4C, whereas secondary Abs were incubated for 1 hr at room temperature
(RT) in 0.1% BSA PBS solution. Samples were stained with mouse-anti-human
E-cadherin Ab (BDBiosciences), a rabbit-anti-humananti-MARCOAb (Abcam),
mouse-anti-human CD206 AF488 (Biolegend), and mouse-anti-human CD163
(AbDSerotec). Secondary goat-anti-mouse IgG(H+L) AF488 and goat-anti-rab-
bit IgG(H+L) AF555 (Life Technologies) were used for detection. Slides were
mounted with DAPI-containing Prolong Diamond mounting medium. Images
were collected using a confocal microscope (Leica TCS SP5 X or LSM-700;
Carl Zeiss). Confocal stack imageswere recordedwith the LSM Image software
and used to generate 3D projections.
Images of three non-overlapping optical fields covering the surface of the
tumor sections were captured. Image analysis was performed in ImageJ using
the area measurement application, and cells were counted double blind.
Cell Staining on Glass Coverslips or Chamber Wells
Cells were seeded in wells for overnight attachment. Prior to Ab incubation, the
cells were incubated for 10 min in ice-cold DMEM, 1% BSA, and 20 mM
HEPES. The cells were stained with anti-CD11b A488, anti-F4/80 A647, and
anti-MARCO AF555 (ED31) for 30 min on ice in dark. The wells were washed
thoroughly with 1% BSA/PBS, and the cells were fixed with 4% PFA for
20 min at RT. The cells were washed with 1% BSA/PBS and mounted with
Prolong Diamond DAKO mounting medium.
IVIS
Animals were imaged in groups of five using an IVIS Spectrum computed
tomography (CT) (PerkinElmer). Mice were injected s.c. with 1 3 105 B16-luc
cells in BD Matrigel. The animals were weighed and shaved locally at the
injection site before imaging. The mice were subsequently injected i.p. with
15 mg/g body weight of the substrate D-Luciferin Potassium salt (Perkin El-
mer). After determining the kinetics curve of luciferin breakdown for the B16-
luc system, the optimal imaging time point was determined at around 15 min
after substrate administration. As the time point of maximal bioluminescence
readout fluctuated with tumor size over the course of the experiment, an imag-
ing sequence of six segments with 5 min delay was captured per imaging ses-
sion. Measurements were taken on days 3, 6, and 9, respectively, of the exper-
imental setup. The mice were anesthetized with isoflurane for the procedure.
Tumor Dissociation Protocol
B16-luc tumors were harvested in cold RPMI on day 10. They were finely cut
into pieces using surgical scalpels and further enzymatically dissociated
through the addition of 200 mg/ml DNase I (Roche), 200 mg/ml hyaluronidase
(Sigma), 66 mg/ml Liberase TL (Roche), and 1 M HEPES for 30–45 min at
37C with stirring. After 20 min of incubation, 0.1 M EDTA was added to avoid
clumping. The samples were incubated for an additional 10 min on ice to allow
isolation of macrophages and dendritic cells. Thereafter, the preparations
were passed through a 100-mm filter strainer and washed thoroughly with
Hank’s balanced salt solution (HBSS) buffer supplemented with 2% FCS,
20 mM HEPES, and 5 mM EDTA. Finally, the cells were resuspended in PBS
and stained for flow cytometry. In some cases, the mouse tumor dissociation
kit from Miltenyi Biotech was used, with no difference in the amount or quality
of the dissociated cells. 4T1 tumors were dissociated using theMiltenyi mouse
tumor dissociation kit according to the manufacturers’ instructions and using
the Gentle MACS dissociator (Miltenyi Biotech).
Flow Cytometry, Cell Sorting, and ELISA
Single-cell suspensions of tumors were prepared, and erythrocytes were
lysed. Non-specific labeling was blocked with anti-CD16/32 (Fc Block;
BioLegend) before specific labeling. LIVE/DEAD Aqua staining was used to
remove dead cells. The cells were fixed and permeabilized (buffers from
BioLegend) after surface staining. For intracellular FoxP3 staining, the manu-
facturer’s protocol was followed (Invitrogen). All fluorescence-activated cell
sorting (FACS) plots depict log10 fluorescence. Cells were stained with the
following rat-anti-mouse Abs from BioLegend: anti-TCRb allophycocyanin
(APC); anti-NK.1.1 PerCP-Cy5.5; anti-CD4 fluorescein isothiocyanate (FITC)/
Pacific blue; anti-CD8 phycoerythrin (PE)/FITC; anti-CD45R Pacific blue/
APC Cy7/ FITC; anti-CD45 APC-Cy7/700; anti-CD11b PECy7; anti-F4/80
APC-Cy7 and Pacific blue; anti-CD11c PerCP-Cy5.5 and PE; anti-Gr-1 Pacific
blue; anti-Ly6G AF488; anti-Ly6C AF647; anti-MHCII PerCP-Cy5.5; anti-
CD49d PE; anti-FoxP3 PE; anti-CD49b APC; anti-CD3-biotin; and streptavi-
din-Qdot605. SINFEKL-specific MHC-I pentamer biotin was used to detect
CD8+-specific T cells (ProImmune). 7AAD or Live/Dead marker Aqua AmCyan
(Life Technologies) was used for live-dead cell discrimination. The samples
were analyzed using a BD LSR Fortessa X-20 cytometer and analyzed with
FlowJo software. For sorting, after tumor dissociation, CD45+ cells were
positively selected from the tumor lysate by magnetic-assisted cell sorting.
Live CD45+ CD11b+ Ly6G cells were sorted as bulk or into the subpopula-
tions Ly6Chi MHCIIlo, Ly6Cint MHCIIhi, Ly6Clo MHChi, and Ly6Clo MHCIIlo
subsets or live CD45+, CD11b+, Ly6G, F4/80, CD11c+ DCs using a BD
FACS Aria fusion cell sorter. For ELISA, OVA-specific IgG1, IgG2a, and
IgG2b Abs from serum of tumor-bearing mice were measured by standard
ELISA technique. The plates (Nunc) were coated overnight at 4C with
10 mg/ml of OVA and blocked with BSA for 2 hr at RT. Serum samples were
diluted from 1/5 to 1/200 in blocking buffer and incubated overnight at 4C.
After washing with PBS with 0.05% Tween 20 (Sigma-Aldrich), horseradish
peroxidase (HRP)-conjugated secondary anti-mouse IgG1, IgG2a, and
IgG2b (Southern Biotech) were used to detect OVA-specific Abs and were
incubated for 1 hr at RT. All Ab levels were expressed as optical density
(OD) at 450 nm.
qPCR
Custom designed primers (Sigma) for qPCR were used to determine expres-
sion of a variety of macrophage polarization and cytokine genes (h2-ab1,
fcgr2b, arg1, marco, nos2, fizz/retnla, ym1/chi3l3, il12a, il12b, cd200r, csf1r,
tgfb, cx3cr1, il10, ccr2, siglec1, cd163, and rpl13a as a housekeeping gene).In-vitro-cultured cells were lysed in RNA later (RLT) buffer with 1% b-mercap-
toethanol (Life Technologies), and RNA preparation was performed using the
QIAGEN Rneasy micro/mini plus kit. cDNA was synthesized using iScript
(Bio-Rad) under standard conditions. qPCR using SYBRGreen (Bio-Rad)
was performed on a CFX96 real-time cycler (Bio-Rad) and analyzed according
to the Livak method for relative expression.
Human Breast Cancer and Melanoma Samples
Tumor tissue from women (n = 18) operated for invasive breast cancer were
collected at Department of Surgery, Umea University. Samples were collected
during surgery, snap frozen in liquid nitrogen, and kept at80C until analysis.
Five-micrometer sections were cut and used for immunofluorescence analysis
as described above. The cohort consisted of tenwomenwith ER- and PR-pos-
itive and ten women with ER- and PR-negative disease, respectively. Eight out
of 20 women had axillary lymph node metastasis at the time of surgery. In re-
gards to molecular subtypes of breast cancer, the cohort consisted of seven
Luminal A, one Luminal B, five Her-2-amplified, and seven triple-negative
breast cancer patients. Informed consent was obtained from all patients.
Ethical approval was obtained from the ethical committee (EPN) of Northern
Sweden. For melanoma, metastases from patients with cutaneous melanoma,
who underwent surgery at the Karolinska University Hospital, were included in
this study. The specimens were fresh frozen in liquid nitrogen and kept in a bio-
bank until analysis. Biobanking and analysis of patient samples was approved
by the Stockholm Regional Ethics Committee.
Statistics
Data were analyzed by unpaired Student’s t test or Mann-Whitney U t test to
compare two groups. A p value of <0.05% was considered to be statistically
significant. Survival was analyzed with the log rank (Mantel-Cox) test.
RNA-Seq Data Processing and Analysis
TCGA Breast Cancer Dataset
Clinical data from the TCGA invasive breast carcinomadataset (provisional) were
downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/) on
11th of December 2013 and included data for 1,148 cases. Unaligned RNA-seq
data from the TCGA dataset were subsequently downloaded (June 2014) after
approval from the TCGA data access committee (n = 1,126; all available cases
with unaligned data). A total of 1,073 cases were available with both unaligned
RNA-seq data and clinical data. Of these, 35 observations were excluded as po-
tential outliers based on inspection of principal-component analysis scores and
residuals. A total of 885 of the 1,038 cases had molecular subtype (PAM50)
assignments available. All remaining cases classified as normal-like subtype
(n = 105)were excluded, as the clinical relevance for this subtype has been ques-
tioned (Eroles et al., 2012), leaving 780 samples for further analysis.
Tissue Collection, RNA Extraction, RNA Library Construction, and
Sequencing for the ClinSeq Breast Cancer Dataset
Tumor tissues from 255 patients diagnosed with breast cancer between 2006
and2010at theKarolinskaHospital and63patientsduring 2012atSouthGeneral
Hospital in Stockholm were snap-frozen on dry ice and stored at 80C. The
ClinSeq breast cancer study has approval from the Regional Ethical Review
Board in Stockholm. RNA was extracted from fresh frozen tumors using AllPrep
DNA/RNA/Protein mini kit (QIAGEN). RNA was assessed using bioanalyzer
to ensure high quality (RNA integrity number [RIN] > 8). One microgram of total
RNA was used for rRNA depletion using RiboZero (Illumina), and stranded
RNA-seq libraries were constructed using a TruSeq Stranded Total RNA Library
Prep Kit (Illumina). Sequencing was performed using an Illumina HiSeq 2500 at
Science for Life Laboratories. In total, the ClinSeq dataset contained 318 cases
with RNA-seq data. Of these, 11 were excluded as potential outliers based on
inspection of principal-component scores and residuals, leaving 307 samples
for analyses.
Bioinformatic Pre-processing of RNA-Seq Data
Standard Illumina adapters (AGATCGGAAGAGCACACGTCTGAACTCCAGT
CAC and AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA) were trimmed
using skewer version 0.1.117 (Jiang et al., 2014) with default parameters
for both single-end and paired-end data. Alignment was conducted using
STAR aligner version 2.4.0e (Dobin et al., 2013) with the following parameters:
‘‘–outSAMmapqUnique 50,’’ to set the mapping quality of uniquely mappedCell Reports 15, 2000–2011, May 31, 2016 2009
reads to 50; ‘‘–outSAMunmapped Within,’’ to include unmapped reads in the
resulting SAM file; ‘‘–chimSegmentMin 20’’ to require that a minimum of 20
bases maps to each end of a chimeric transcript (output in a separate file);
and ‘‘–outSAMattributes NH HI AS nM NMMD XS,’’ to include additional attri-
butes in the SAM file. Gene expression estimates were calculated with HTSeq
count version 0.6.0 (Anders et al., 2015) with the following parameters: ‘‘–stran-
ded=no’’ for TCGA, because the TCGA Breast Cancer RNA-seq data are
non-stranded or ‘‘–stranded=reverse’’ for ClinSeq data and ‘‘—mode = inter-
section-nonempty’’ for counting reads. The RNA-seq count data were normal-
ized using the TMM method (Robinson and Oshlack, 2010) provided in the
edgeRpackage (Robinson et al., 2010). Gene expression values are expressed
as log2 (counts per million), abbreviated as log2 (CPM). Molecular subtypes of
tumors in theClinSeqdatasetwere assignedbyapplying themethoddescribed
by Parker et al. (2009) and using the TCGA dataset to estimate model pa-
rameters. To account for potential batch differences, the two datasets were
pre-processed using the same bioinformatic pipeline and variables were
mean-centered and scaled to unit variance. Marginal correlation between
MARCOandgenes in the ‘‘M2gene set’’ and the ‘‘EMTgene set’’ was assessed
by means of Spearman’s rank correlation coefficient (rho) with p values based
on a two-sided test, using the cor.test function inR,with p values calculated us-
ing the function pSpearman() in the R package ‘‘SuppDists’’. RNA-seq gene
expression data (RNaseq v2 [level 3]; quantified by RNA-seq by expectation
maximization (RSEM); Li and Dewey, 2011) from 469 Skin Cutaneous Mela-
noma patients were downloaded from TCGA data portal together with clinical
data. RNA-seq data were normalized using the same method as described
above. Sampleswith ‘‘submitted tumor site’’ annotatedas ‘‘distantmetastasis’’
(n = 68), ‘‘primary tumor’’ (n = 102), ‘‘local cutaneous or subcutaneous tissue’’
(includes satellite and in-transit metastasis) (n = 74), or ‘‘local lymph node’’
(n = 222) were used in subsequent analyses (466 tumors in total).
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